Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
International comparison sits at the center of this dementia and brain health question.
Recent research demonstrates that dementia rates are indeed declining in countries with better cardiovascular care systems. Large-scale international studies reveal a striking pattern: as nations have improved their management of heart disease, high blood pressure, diabetes, and stroke risk, the incidence and prevalence of dementia have correspondingly fallen. The Framingham Heart Study, which followed three generations in Massachusetts, documented a remarkable 44% decline in dementia rates over three decades—from 3.6 cases per 100 people in the late 1970s and early 1980s to just 2.0 per 100 people by the early 2010s. This is not a coincidence. The brain depends entirely on cardiovascular health for its oxygen and nutrient supply, and when researchers examined populations across different healthcare systems, those with stronger cardiovascular disease management consistently showed lower dementia rates.
This connection has emerged as one of the most important findings in neurology and preventive medicine. The Netherlands-based Rotterdam Study found a 25% reduction in dementia cases when comparing two birth cohorts a decade apart—one from 1990 and another from 2000. A meta-analysis of 25 major studies published between 2007 and 2021 confirmed what individual studies had shown: cardiovascular disease, poorly controlled hypertension, unmanaged diabetes, and elevated cholesterol are all strong risk factors for cognitive decline and dementia. The evidence points to a hopeful conclusion: dementia is not inevitable. In countries where healthcare systems have made cardiovascular risk a priority, people are living longer with their minds intact.
Table of Contents
- Are Dementia Rates Declining Globally, or Only in Wealthy Countries?
- What Specific Cardiovascular Improvements Are Driving the Dementia Decline?
- How Do International Healthcare Systems Compare in Cardiovascular Disease Prevention?
- What Cardiovascular Health Metrics Most Strongly Protect Against Dementia?
- What Are the Limitations of the Cardiovascular-Dementia Connection Studies?
- Can Cardiovascular Medications Prevent Dementia Directly, or Is It Just a Correlation?
- What Does the International Evidence Suggest for Future Dementia Trends?
- Conclusion
Are Dementia Rates Declining Globally, or Only in Wealthy Countries?
The dementia decline has been dramatic in high-income nations but unequally distributed. A large population-based analysis spanning 40 years showed a stunning two-thirds reduction in dementia prevalence across developed countries. To put this in concrete terms: in 1984, approximately 30% of people aged 85 to 89 had dementia; by 2024, that figure had dropped to just 10%. This represents a genuine shift in the epidemiology of aging. Research tracking temporal trends between 1988 and 2015 found a 13% decrease in dementia incidence and prevalence for each decade in higher-income regions, particularly in North America and Europe.
However, this progress is geographically concentrated. Lower-income countries, where cardiovascular care infrastructure is less developed, have not experienced the same declines. China, for example, has a rising dementia burden even as certain cities implement better heart disease prevention programs. The contrast is instructive: a 2025 study involving nearly 34,000 adults over 40 with uncontrolled hypertension in rural China demonstrated that those who received structured intervention treatment were notably less likely to develop dementia than untreated peers. This reveals the limitation of current progress—it remains mostly accessible to populations with robust healthcare systems. The global picture is one of divergence, not universal progress.
What Specific Cardiovascular Improvements Are Driving the Dementia Decline?
The cardiovascular risk factors most strongly linked to dementia prevention include three key areas: hypertension control, metabolic disease management, and smoking reduction. When doctors successfully control blood pressure, the brain’s small blood vessels remain healthy, and chronic inflammation in the brain decreases. Similarly, managing type 2 diabetes prevents the cascade of vascular damage that impairs cognitive function. Smoking reduction across developed nations has been particularly important—smoking damages blood vessel walls and accelerates cognitive aging. Each of these factors, when improved at the population level, has contributed measurably to fewer dementia cases.
But there are important caveats. Not everyone benefits equally. The research shows these improvements work best in people who already have access to healthcare and who can afford medications. Someone with hypertension who has never been diagnosed, or who cannot afford blood pressure medication, gains no protection from these advances. Additionally, simply lowering blood pressure does not guarantee dementia prevention if other factors—such as physical inactivity, cognitive disengagement, or poor diet—remain unaddressed. The studies demonstrate correlation and mechanism, but they also reveal that cardiovascular care is necessary but not sufficient on its own.
How Do International Healthcare Systems Compare in Cardiovascular Disease Prevention?
Healthcare systems that prioritize early screening and prevention have seen the steepest dementia declines. In Scandinavian countries, for instance, routine cardiovascular risk assessment begins in middle age, and medications like statins and antihypertensives are distributed widely and at low cost. The Netherlands has integrated cardiovascular and cognitive screening, understanding that protecting the heart protects the mind. The United States, despite high healthcare spending, shows mixed results—excellent outcomes in well-insured populations but significant disparities for underinsured groups.
China’s experience offers a revealing contrast. Rural areas with less structured cardiovascular management showed rising dementia rates even as urban centers with better healthcare infrastructure saw improvements. The 2025 hypertension intervention study in China found that structured treatment—meaning regular monitoring, medication adherence, and lifestyle counseling—reduced dementia risk substantially. This demonstrates that the dementia decline is not automatic or genetic; it requires active health system engagement. Countries that have invested in primary care infrastructure and preventive medications have reaped cognitive benefits across their populations.
What Cardiovascular Health Metrics Most Strongly Protect Against Dementia?
Research identifies seven key metrics that correlate with dementia prevention: controlled blood pressure (below 130/80 mmHg), LDL cholesterol below 70 mg/dL in high-risk patients, fasting blood sugar below 100 mg/dL, regular physical activity (at least 150 minutes weekly), non-smoking status, healthy weight, and absence of atrial fibrillation. Each metric adds a layer of protection. Someone who achieves all seven has dramatically lower dementia risk than someone with none. The Framingham data suggest that achieving these metrics by age 50 provides protection that extends three decades or more into old age.
The tradeoff, however, is that achieving these metrics requires sustained effort and access to healthcare. A person might maintain excellent blood pressure control at age 60 but become less diligent at 75, when they grow tired of taking medications. Cost is another factor—antihypertensive medications are inexpensive in wealthy countries but prohibitively expensive elsewhere. Furthermore, some populations have genetic predispositions to hypertension or diabetes that require higher medication doses, making prevention more complex and potentially more expensive. The research shows what works but doesn’t always address the real-world barriers to implementation.
What Are the Limitations of the Cardiovascular-Dementia Connection Studies?
Most large dementia studies have been conducted in North America and Europe, limiting the generalizability of findings to non-Western populations. Genetic differences, dietary patterns, and healthcare traditions vary globally, and what protects cognition in one population might differ slightly in another. Additionally, many studies are observational rather than randomized controlled trials, meaning researchers can document that people with better cardiovascular health have lower dementia rates, but proving causation is harder. Reverse causation is also possible—early cognitive decline might reduce physical activity and cardiovascular health, rather than cardiovascular disease causing dementia. A critical warning: improved cardiovascular care has extended lifespan significantly, shifting the average age at which dementia appears.
Rather than eliminating dementia entirely, population-level improvements have delayed its onset. A person who would have had a stroke and died at 70 in 1980 might now live to 85 with managed hypertension, and thus encounter dementia risk later in life. Dementia has not been prevented so much as deferred. For individuals and families, this is positive—more years of cognitive health. But for society, rising numbers of very old people means dementia prevalence will continue climbing in absolute terms, even as age-adjusted rates fall.
Can Cardiovascular Medications Prevent Dementia Directly, or Is It Just a Correlation?
Specific cardiovascular medications show promise in dementia prevention, though the mechanism isn’t fully understood. Blood pressure medications, particularly ACE inhibitors and angiotensin receptor blockers, appear to have neuroprotective properties beyond simply lowering blood pressure—they reduce brain inflammation. Statins lower cholesterol but also have anti-inflammatory effects in brain tissue. These medications seem to work partly through their direct cardiovascular effects and partly through separate neuroprotective pathways.
A person taking these medications is getting dual benefit: a healthier heart and a more protected brain. An example illustrates this: a 65-year-old man with hypertension and high cholesterol who takes an antihypertensive and a statin experiences not just a reduced risk of heart attack, but also a reduced risk of cognitive decline. The medications protect his coronary arteries and simultaneously calm the neuroinflammation that drives Alzheimer’s pathology. However, the research does not yet show that taking these medications without actually improving underlying cardiovascular health—say, while continuing to smoke and remain sedentary—provides the full cognitive benefit. The medications work best within a framework of genuine lifestyle improvement.
What Does the International Evidence Suggest for Future Dementia Trends?
If current trends continue, dementia rates in high-income countries will likely continue declining through mid-century, assuming healthcare systems maintain their focus on cardiovascular prevention. Emerging economies that are rapidly improving their cardiovascular care infrastructure—parts of China, Brazil, and India—may see similar declines in coming decades. The 2025 hypertension studies suggest that even relatively simple interventions, like regular medication monitoring and lifestyle counseling, can meaningfully reduce dementia incidence in previously underserved populations. This offers hope that the dementia decline need not remain a privilege of the wealthy. However, global inequality in dementia burden will likely persist.
Low-income countries without strong primary care systems will continue to experience rising dementia rates as populations age. The international evidence suggests that dementia prevention is achievable and scalable but requires sustained investment in cardiovascular health infrastructure. The countries showing the greatest progress are those that have treated cardiovascular disease prevention as a public health imperative, not a luxury service. The lesson from the international comparison is clear: dementia rates are not fixed by genetics or fate. They respond to health system design and to population-level choices about cardiovascular prevention.
Conclusion
The international research is unequivocal: dementia is declining in countries with better cardiovascular care. The Framingham Heart Study’s 44% reduction, the Rotterdam Study’s 25% improvement, and the 67% drop in dementia risk over four decades all point to a powerful truth—protecting the heart protects the brain. As nations have improved the management of hypertension, diabetes, cholesterol, and smoking, their populations have experienced fewer cognitive impairments in old age. The mechanism is straightforward: the brain cannot survive without a healthy cardiovascular system, and when that system is well-maintained, cognitive resilience follows. The challenge ahead is equity.
The dementia decline remains concentrated in high-income countries with mature healthcare systems. For dementia rates to fall globally, lower-income nations need investment in primary care, accessible medications, and public health campaigns around cardiovascular prevention. The evidence from China and elsewhere shows this is possible—structured cardiovascular interventions demonstrably reduce dementia risk even in resource-limited settings. The international comparison study reveals not a mystery to be solved but a roadmap to be followed: dementia prevention is achievable for any population willing to prioritize cardiovascular health. The question is not whether dementia rates can decline, but whether the world will make the investments necessary to ensure that decline reaches everyone.
You Might Also Like
- The Indoor Air Quality Study That Found Higher Dementia Rates in Homes With Poor Ventilation
- The Respite Care Voucher Program That Gives Dementia Caregivers $500 Per Month for Any Type of Relief
- Why Comprehensive Hearing Vision and Dental Care Should Be Standard Dementia Prevention
For more, see National Institute on Aging.
